OnKure Therapeutics, Inc. vs Insmed Incorporated
A head-to-head of OnKure Therapeutics, Inc. (OKUR) and Insmed Incorporated (INSM) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | OKUR | INSM |
|---|---|---|
| Market Cap | $168.45M | $23.54B |
| P/E (TTM) | — | — |
| Forward P/E | 0.00 | 290.45 |
| P/S | 0.00 | 28.34 |
| P/B | 1.00 | 33.37 |
| EV/EBITDA | 0.57 | -23.96 |
| Dividend Yield | — | — |
| Profit Margin | 0.00% | -144.44% |
| Gross Margin | — | 79.73% |
| Operating Margin | 0.00% | -164.04% |
| Revenue Growth (YoY) | 0.00% | +229.62% |
| FCF Yield | -24.19% | -3.97% |
| Debt / Equity | 0.98 | 76.93 |
| Current Ratio | 10.28 | 4.47 |
Which is better: OnKure Therapeutics, Inc. or Insmed Incorporated?
- ✓Larger by market cap: Insmed Incorporated
- ✓More profitable (net margin): OnKure Therapeutics, Inc.
- ✓Faster revenue growth: Insmed Incorporated
- ✓Higher free-cash-flow yield: Insmed Incorporated
Across 7 available metrics, OnKure Therapeutics, Inc. leads 5–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare OnKure Therapeutics, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.